// App-Quantinova.ai

3841 : The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Researchers

Presenter

  • Denise Niewerth

Principal Investigators

  • Johan van Meerloo

  • Yehuda Assaraf

  • Gerrit Jansen

  • Tessa C Hendrickx

  • Christopher J. Kirk

  • Janet Anderl

  • Sonja Zweegman

  • Jacqueline Cloos

  • Gertjan Kaspers

Medical Centers

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, Netherlands

  • The Fred Wyszkowski Cancer Research Lab, Technion-Israel Institute of Technology, Haifa, Israel

Locations

  • Israel

  • Netherlands

Companies

  • Onyx Pharmaceuticals

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Acute myelocytic leukemia

  • Acute Leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Progesterone receptor

  • Proteasome Subunit Beta 5

  • Proteasome Subunit Beta 8

Drug/Treatment

  • carfilzomib Intravenous

  • Bortezomib

  • PR924

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved